74 related articles for article (PubMed ID: 22119622)
1. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA.
Stiles DK; Zhang Z; Ge P; Nelson B; Grondin R; Ai Y; Hardy P; Nelson PT; Guzaev AP; Butt MT; Charisse K; Kosovrasti V; Tchangov L; Meys M; Maier M; Nechev L; Manoharan M; Kaemmerer WF; Gwost D; Stewart GR; Gash DM; Sah DW
Exp Neurol; 2012 Jan; 233(1):463-71. PubMed ID: 22119622
[TBL] [Abstract][Full Text] [Related]
2. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease.
McBride JL; Pitzer MR; Boudreau RL; Dufour B; Hobbs T; Ojeda SR; Davidson BL
Mol Ther; 2011 Dec; 19(12):2152-62. PubMed ID: 22031240
[TBL] [Abstract][Full Text] [Related]
3. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.
Boudreau RL; McBride JL; Martins I; Shen S; Xing Y; Carter BJ; Davidson BL
Mol Ther; 2009 Jun; 17(6):1053-63. PubMed ID: 19240687
[TBL] [Abstract][Full Text] [Related]
4. A programmable dual-targeting siRNA scaffold supports potent two-gene modulation in the central nervous system.
Belgrad J; Tang Q; Hildebrand S; Summers A; Sapp E; Echeverria D; O'Reilly D; Luu E; Bramato B; Allen S; Cooper D; Alterman J; Yamada K; Aronin N; DiFiglia M; Khvorova A
Nucleic Acids Res; 2024 Jun; 52(11):6099-6113. PubMed ID: 38726879
[TBL] [Abstract][Full Text] [Related]
5. Convection-enhanced delivery of botulinum toxin serotype A into the nonhuman primate cisterna magna and hippocampus.
Argersinger DP; Walbridge S; Wetjen NM; Vortmeyer AO; Wu T; Butman JA; Heiss JD
J Neurosurg; 2019 Jul; 133(2):588-595. PubMed ID: 31323637
[TBL] [Abstract][Full Text] [Related]
6. Genetic Testing of HTT Modifiers for Huntington's Disease: Considerations for Clinical Guidelines.
Goldman JS; Uhlmann WR; Naini AB; Klitzman RL; Marder KS
Mov Disord; 2023 Dec; 38(12):2151-2154. PubMed ID: 37975739
[No Abstract] [Full Text] [Related]
7. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.
Kordasiewicz HB; Stanek LM; Wancewicz EV; Mazur C; McAlonis MM; Pytel KA; Artates JW; Weiss A; Cheng SH; Shihabuddin LS; Hung G; Bennett CF; Cleveland DW
Neuron; 2012 Jun; 74(6):1031-44. PubMed ID: 22726834
[TBL] [Abstract][Full Text] [Related]
8. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.
Grondin R; Kaytor MD; Ai Y; Nelson PT; Thakker DR; Heisel J; Weatherspoon MR; Blum JL; Burright EN; Zhang Z; Kaemmerer WF
Brain; 2012 Apr; 135(Pt 4):1197-209. PubMed ID: 22252996
[TBL] [Abstract][Full Text] [Related]
9. Onset Time and Durability of Huntingtin Suppression in Rhesus Putamen After Direct Infusion of Antihuntingtin siRNA.
Grondin R; Ge P; Chen Q; Sutherland JE; Zhang Z; Gash DM; Stiles DK; Stewart GR; Sah DW; Kaemmerer WF
Mol Ther Nucleic Acids; 2015 Jun; 4(6):e245. PubMed ID: 26125484
[TBL] [Abstract][Full Text] [Related]
10. Huntington's Disease: Understanding Its Novel Drugs and Treatments.
Dhingra H; Gaidhane SA
Cureus; 2023 Oct; 15(10):e47526. PubMed ID: 38021751
[TBL] [Abstract][Full Text] [Related]
11. Insights into White Matter Defect in Huntington's Disease.
Sun Y; Tong H; Yang T; Liu L; Li XJ; Li S
Cells; 2022 Oct; 11(21):. PubMed ID: 36359783
[TBL] [Abstract][Full Text] [Related]
12. Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment.
Pandey N; Anastasiadis P; Carney CP; Kanvinde PP; Woodworth GF; Winkles JA; Kim AJ
Adv Drug Deliv Rev; 2022 Sep; 188():114415. PubMed ID: 35787387
[TBL] [Abstract][Full Text] [Related]
13. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.
Tabrizi SJ; Estevez-Fraga C; van Roon-Mom WMC; Flower MD; Scahill RI; Wild EJ; Muñoz-Sanjuan I; Sampaio C; Rosser AE; Leavitt BR
Lancet Neurol; 2022 Jul; 21(7):645-658. PubMed ID: 35716694
[TBL] [Abstract][Full Text] [Related]
14. Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic.
Rook ME; Southwell AL
BioDrugs; 2022 Mar; 36(2):105-119. PubMed ID: 35254632
[TBL] [Abstract][Full Text] [Related]
15. Gene Therapy for Huntington's Disease: The Final Strategy for a Cure?
Byun S; Lee M; Kim M
J Mov Disord; 2022 Jan; 15(1):15-20. PubMed ID: 34781633
[TBL] [Abstract][Full Text] [Related]
16. Huntingtin Lowering Strategies.
Marxreiter F; Stemick J; Kohl Z
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245050
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in the Treatment of Huntington's Disease: Targeting DNA and RNA.
Shannon KM
CNS Drugs; 2020 Mar; 34(3):219-228. PubMed ID: 31933283
[TBL] [Abstract][Full Text] [Related]
18. The Emerging Role of microRNAs in Polyglutamine Diseases.
Dong X; Cong S
Front Mol Neurosci; 2019; 12():156. PubMed ID: 31275113
[TBL] [Abstract][Full Text] [Related]
19. Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease.
Zeitler B; Froelich S; Marlen K; Shivak DA; Yu Q; Li D; Pearl JR; Miller JC; Zhang L; Paschon DE; Hinkley SJ; Ankoudinova I; Lam S; Guschin D; Kopan L; Cherone JM; Nguyen HB; Qiao G; Ataei Y; Mendel MC; Amora R; Surosky R; Laganiere J; Vu BJ; Narayanan A; Sedaghat Y; Tillack K; Thiede C; Gärtner A; Kwak S; Bard J; Mrzljak L; Park L; Heikkinen T; Lehtimäki KK; Svedberg MM; Häggkvist J; Tari L; Tóth M; Varrone A; Halldin C; Kudwa AE; Ramboz S; Day M; Kondapalli J; Surmeier DJ; Urnov FD; Gregory PD; Rebar EJ; Muñoz-Sanjuán I; Zhang HS
Nat Med; 2019 Jul; 25(7):1131-1142. PubMed ID: 31263285
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
